$CSL Ltd (CSL.AU)$ shares fell 2.37% on Friday, with trading volume expanding to A$147.23 million. CSL has fallen 3.21% over the past week, with a cumulative loss of 2.37% year-to-date.
CSL's technical analysis chart:
Technical Analysis:
Support: A$276
Resistance: A$302.18Price range A$276 to A$302.18: The trading range indicates a heavy concentration of selling orders, with the stock price on an downward trend. There's a high concentration of trapped positions within the trading range, which implies strong resistance to any upward movement. The stock started to decline near A$302.18 due to selling pressure and repeatedly touched the A$276 level, where it seems to find some support. Going forward, it's crucial to watch whether the support at A$276 holds and if it can lead to a potential rebound.
Market News :
CSL faced difficulties in the recruitment and dosing stages of its Kcentra trial, which affected the feasibility and sample size of the study. Additionally, CSL did not achieve the primary efficacy endpoint for Hizentra, its treatment for primary immune deficiency, leading to the discontinuation of the associated study. The company made a similar decision regarding a trial on clazakizumab, stating that it is not expected to achieve the ultimate primary efficacy goal.
The Trump administration's potential imposition of tariffs may force Australian-listed pharmaceutical and medical device manufacturers to consider relocating their production. The company might need to evaluate the sources of various inputs and production locations. While tariffs could drive the relocation of facilities to the United States, this could result in a decrease in the companies' profitability.
Overall Analysis:
Fundamentally, focus on the company's performance and operational status. Technically, pay attention to whether the support levels hold and if the resistance levels can be effectively breached.
In this scenario, investors should adopt a cautious strategy, setting stop-loss points to manage risk and maintaining ongoing vigilance regarding company developments and market conditions.
Source: CSL, Bloomberg
